Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis

Published:2024 Issue:2 Volume:13 Page:83
ISSN:2287-3651
Container-title:Clinical and Experimental Vaccine Research
language:en
Short-container-title:Clin Exp Vaccine Res

Author:

Salajegheh Faranak¹^ORCID,Rukerd Mohammad Rezaei Zadeh²^ORCID,Nakhaie Mohsen²^ORCID,Ghoreshi Zohreh-Al-Sadat³^ORCID,Charostad Javad⁴^ORCID,Arefinia Nasir³⁵^ORCID

Affiliation:

1. Clinical Research Development Unit, School of Medicine, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.

2. Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.

3. School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.

4. Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran.

5. Bio Environmental Health Hazards Research Center, Jiroft University of Medical Sciences, Jiroft, Iran.

Publisher

XMLink

Link

https://ecevr.org/pdf/10.7774/cevr.2024.13.2.83

Reference33 articles.

1. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency

2. The Effect of Intravenous Tocilizumab Therapy on the Prognosis of Patients with COVID-19: A Case-Control Study

3. Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality

4. Who should be prioritised for COVID-19 vaccination?

5. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents